Pancreatic Cancer Research

ResearcherCasa Sollievo della SofferenzaActive in the last 2 years

Francesco Perri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8314-8016; OpenAlex author ID A5091031530. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 7 papers · 2024: 3 papers · 2025: 4 papers

Papers 20

  1. Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and B… Co-author DOI 10.1002/cam4.71450↗
  2. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  3. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  4. Could the Microbial Profiling of Normal Pancreatic Tissue from Healthy Organ Donors Contribute to Understanding the Intratumoral Microbiota Signature in Pancre… Last author DOI 10.3390/microorganisms13020452↗
  5. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  6. A powerful machine learning approach to identify interactions of differentially abundant gut microbial subsets in patients with metastatic and non-metastatic p… Co-author DOI 10.1080/19490976.2024.2375483↗
  7. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  8. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  9. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  10. Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS G12D mutated pancreatic cancer in vivo model. Co-author DOI 10.1038/s41420-023-01397-y↗
  11. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  12. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  13. Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study. Last author DOI 10.1186/s10020-023-00600-1↗
  14. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  15. Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models. Co-author DOI 10.1016/j.biopha.2022.113163↗
  16. Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspe… Co-author DOI 10.1016/j.semcancer.2021.11.007↗
  17. Tuning gut microbiota through a probiotic blend in gemcitabine-treated pancreatic cancer xenografted mice. Co-author DOI 10.1002/ctm2.580↗
  18. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  19. Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels. Co-author DOI 10.3390/biom11050639↗
  20. High Levels of Prebiotic Resistant Starch in Diet Modulate a Specific Pattern of miRNAs Expression Profile Associated to a Better Overall Survival in Pancreati… Co-author DOI 10.3390/biom11010026↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tiziana Pia Latiano · 10 shared papers, 2020–2025 · strength 1.64
  2. Annacandida Villani · 8 shared papers, 2020–2025 · strength 1.25
  3. Concetta Panebianco · 8 shared papers, 2020–2025 · strength 1.25
  4. Valerio Pazienza · 8 shared papers, 2020–2025 · strength 1.25
  5. Evaristo Maiello · 4 shared papers, 2022–2025 · strength 0.75
  6. Francesca Tavano · 3 shared papers, 2023–2025 · strength 0.50
  7. Andrea Fontana · 2 shared papers, 2023–2024 · strength 0.35
  8. Nadia Trivieri · 2 shared papers, 2020–2021 · strength 0.25
  9. Fabio F. di Mola · 1 shared paper, 2025 · strength 0.22
  10. Tommaso Mazza · 1 shared paper, 2025 · strength 0.22
  11. Tamás Hussein · 1 shared paper, 2023 · strength 0.11
  12. Ștefania Bunduc · 1 shared paper, 2023 · strength 0.11
  13. Emanuele F. Kauffmann · 1 shared paper, 2023 · strength 0.11
  14. Andrea Mambrini · 1 shared paper, 2023 · strength 0.11
  15. Martin Loveček · 1 shared paper, 2023 · strength 0.11
  16. Marta Puzzono · 1 shared paper, 2023 · strength 0.11
  17. Matteo Giaccherini · 1 shared paper, 2023 · strength 0.11
  18. Federico Canzian · 1 shared paper, 2023 · strength 0.11
  19. Riccardo Farinella · 1 shared paper, 2023 · strength 0.11
  20. Thilo Hackert · 1 shared paper, 2023 · strength 0.11
  21. Giulia Martina Cavestro · 1 shared paper, 2023 · strength 0.11
  22. Pavel Vodička · 1 shared paper, 2023 · strength 0.11
  23. Rita Teresa Lawlor · 1 shared paper, 2023 · strength 0.11
  24. Lívia Archibugi · 1 shared paper, 2023 · strength 0.11
  25. Silvia Carrara · 1 shared paper, 2023 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.